On November 7th, 2023, the Federal Trade Commission (FTC) challenged the validity of over 100 patents related to asthma treatment. These patents are currently held by 10 major pharmaceutical manufacturers, including AstraZeneca, Teva, and GlaxoSmithKline. The claim suggests that these manufacturers listed inaccurate patents inside the United States Food and Drug Administration’s Orange Book.
The issue at hand raises concerns around the integrity of corporate practices within the pharmaceutical industry, given the substantial influence these companies have over asthma treatment and medication. The purported inaccuracies in the patents are yet to be publicly disclosed, but the FTC’s challenge has brought them to the limelight.
This news falls into a broader pattern of scrutiny over how pharmaceutical companies list their patents with the FDA. Further details about these allegations and the outcome of this challenge are yet to be unveiled.